At Aqsens Health we are focusing on developing screening solutions for diseases that are hardest to diagnose and/or where the benefits of early diagnosis are the biggest. Hence, we have mainly been focusing on developing the applications to screen for different cancers, and additionally worked intensively on inflammatory bowel diseases, as they become more and more common.
You can read more of the applications we have under development below. We are also continuously adding more applications to our development pipeline and conducting feasibility tests with applications for different diseases.
IBDs - Crohn’s disease and ulcerative colitis - are becoming more and more prevalent especially in the developed countries. They are often hard to diagnose and it make take a long time from the first symptoms to finding an effective treatment, which means the patients suffer from disturbing symptoms that also affect their capability to work and live normally. Furthermore, IBDs are connected to more severe diseases, like bowel cancer and also because of that, it benefits both patients and the healthcare system to diagnose them as early as possible.
Aqsens Health’s E-TRF method is able to detect and categorise the IBDs from a fecal sample, and the application for this is currently under validation testing in Finland.
AQ IBD® (general availability 2Q 2020)
AQ COLON® (under preparation)
In many parts of the world, prostate cancer is the most common cancer amongst men, and also causing most of the cancer deaths amongst men. However, it is even more common: many prostate cancers are left undiagnosed, and many of them never affect the patient during their lifetime. On the other hand, due to low specificity of the current screening methods, it is also overdiagnosed and overtreated. The important mission here is to be able to find early the lethal types of prostate cancer, and for that there are no suitable screening methods available.
Based on early tests, it looks like Aqsens Health’s method can screen and categorise the lethal prostate cancers from urine with its’ accurate and quick method. The application for prostate cancer screening is currently being tested and as a part of that, a vast amount of further testing is being made.
AQ PROSTATE® (clinical validation phase)
Oral cancer, being one of the most common cancers in India, constitutes a significant health burden to the Indian society. It is hard to prevent due to rooted traditions of using tobacco products, but still early detection can dramatically decrease the cost of treatment as well as improve the quality of life of the patients.
Aqsens Health’s mobile screening method can detect oral cancer from a saliva sample that is easy to collect, and the analysis for fast and accurate results can be done also in rural conditions. The work for oral cancer application validation is done in India in collaboration with the Public Health Foundation of India.
AQ ORAL® (clinical validation phase)
Breast cancer is a world-wide challenge in women’s health, and in most countries the most common cancer amongst women. Even though many countries have implemented screening programs to detect it early, there are still more than 600 000 women dying of it annually - which means one death every minute. With more comprehensive screening and following early detection, this amount could be a lot lower.
Aqsens Health started to test its method for breast cancer screening in late 2019. The early results are promising and further tests and development is now being executed.
AQ Breast® (clinical validation phase)